Order Article Reprints

Raphael A, Dudnik E, Hershkovitz D, Jain S, Olsen S, Soussan-Gutman L, Ben-Shitrit T, Dvir A, Nechushtan H, Peled N, et al. FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). Journal of Clinical Medicine. 2022; 11(9):2475. https://doi.org/10.3390/jcm11092475

Raphael, Ari, Elizabeth Dudnik, Dov Hershkovitz, Suyog Jain, Steve Olsen, Lior Soussan-Gutman, Taly Ben-Shitrit, Addie Dvir, Hovav Nechushtan, Nir Peled, and et al. 2022. "FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)" Journal of Clinical Medicine 11, no. 9: 2475. https://doi.org/10.3390/jcm11092475

Raphael, A., Dudnik, E., Hershkovitz, D., Jain, S., Olsen, S., Soussan-Gutman, L., Ben-Shitrit, T., Dvir, A., Nechushtan, H., Peled, N., Onn, A., Agbarya, A., & on behalf of the Israel Lung Cancer Group. (2022). FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). Journal of Clinical Medicine, 11(9), 2475. https://doi.org/10.3390/jcm11092475